{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:39:38Z","timestamp":1792111178730,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03032-3","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:54:18Z","timestamp":1732276458000},"page":"427-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors"],"prefix":"10.1007","volume":"42","author":[{"given":"Robert","family":"Klamroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-4479","authenticated-orcid":false,"given":"Nana","family":"Kragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Guyot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Wdowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Margas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bystrick\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/2040620717746312","volume":"9","author":"P Balkaransingh","year":"2018","unstructured":"Balkaransingh P, Young G. Novel therapies and current clinical progress in hemophilia A. Ther Adv Hematol. 2018;9:49\u201361.","journal-title":"Ther Adv Hematol"},{"key":"3032_CR2","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"3032_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/JBM.S103796","volume":"8","author":"K Lieuw","year":"2017","unstructured":"Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med. 2017;8:67\u201373.","journal-title":"J Blood Med"},{"key":"3032_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","volume":"9","author":"J Wight","year":"2003","unstructured":"Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418\u201335.","journal-title":"Haemophilia"},{"key":"3032_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2516.2011.02682.x","volume":"18","author":"M Olivieri","year":"2012","unstructured":"Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia. 2012;18:369\u201374.","journal-title":"Haemophilia"},{"key":"3032_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1600-0609.2012.01750.x","volume":"88","author":"M Khawaji","year":"2012","unstructured":"Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol. 2012;88:329\u201335.","journal-title":"Eur J Haematol"},{"key":"3032_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/bjh.14844","volume":"179","author":"NG Andersson","year":"2017","unstructured":"Andersson NG, Auerswald G, Barnes C, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol. 2017;179:298\u2013307.","journal-title":"Br J Haematol"},{"key":"3032_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/bloodadvances.2021006119","volume":"6","author":"T Lissitchkov","year":"2022","unstructured":"Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6:1089\u201394.","journal-title":"Blood Adv"},{"key":"3032_CR9","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","volume":"383","author":"BA Konkle","year":"2020","unstructured":"Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020;383:1018\u201327.","journal-title":"N Engl J Med"},{"key":"3032_CR10","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood.2019001292","volume":"135","author":"E Seth Chhabra","year":"2020","unstructured":"Seth Chhabra E, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020;135:1484\u201396.","journal-title":"Blood"},{"key":"3032_CR11","unstructured":"United States Food & Drug Administration. ALTUVIIIO Highlights of Prescribing Information. 2023. https:\/\/products.sanofi.us\/altuviiio\/altuviiio.pdf. Accessed October 2023."},{"key":"3032_CR12","doi-asserted-by":"crossref","unstructured":"Lynn M, Flora P, Anthony KC, et al. Efanesoctocog alfa prophylaxis for previously treated patients <12 years of age with severe hemophilia A (LB 01.1). Res Pract Thromb Haemost. 2023;7(Suppl. 2):1.","DOI":"10.1016\/j.rpth.2023.100288"},{"key":"3032_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388:310\u20138.","journal-title":"N Engl J Med"},{"key":"3032_CR14","unstructured":"Sobi. EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A (Press Release). 2023. https:\/\/www.sobi.com\/en\/press-releases\/ema-validates-marketing-authorisation-application-efanesoctocog-alfa-treatment-haemophilia-2128255. Accessed July 2024."},{"issue":"Suppl. 2","key":"3032_CR15","first-page":"116","volume":"7","author":"S Susen","year":"2023","unstructured":"Susen S, Kulkarni R, Nogami K, et al. Outcomes in adult and adolescent patients with severe hemophilia A in the phase 3 XTEND-1 study who switched to efanesoctocog alfa prophylaxis from an observational study with factor VIII prophylaxis (OC 69.5). Res Pract Thromb Haemost. 2023;7(Suppl. 2):116.","journal-title":"Res Pract Thromb Haemost."},{"issue":"Suppl. 2","key":"3032_CR16","first-page":"691","volume":"7","author":"M Alvarez-Rom\u00e1n","year":"2023","unstructured":"Alvarez-Rom\u00e1n M, Kragh N, Guyot P, et al. Efanesoctocog alfa versus emicizumab in the prophylactic treatment of adolescents and adults with severe hemophilia A without inhibitors: a matching-adjusted indirect comparison (PB0195). Res Pract Thromb Haemost. 2023;7(Suppl. 2):691.","journal-title":"Res Pract Thromb Haemost"},{"key":"3032_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2516.2004.00932.x","volume":"10","author":"MD Tarantino","year":"2004","unstructured":"Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma\/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10:428\u201337.","journal-title":"Haemophilia"},{"key":"3032_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","volume":"10","author":"LA Valentino","year":"2012","unstructured":"Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10:359\u201367.","journal-title":"J Thromb Haemost"},{"key":"3032_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/hae.12952","volume":"22","author":"K Saxena","year":"2016","unstructured":"Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81\u20138973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016;22:706\u201312.","journal-title":"Haemophilia"},{"key":"3032_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/jth.12828","volume":"13","author":"K Kavakli","year":"2015","unstructured":"Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M. Prophylaxis vs. on-demand treatment with BAY 81\u20138973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13:360\u20139.","journal-title":"J Thromb Haemost."},{"key":"3032_CR21","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","volume":"126","author":"BA Konkle","year":"2015","unstructured":"Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126:1078\u201385.","journal-title":"Blood"},{"key":"3032_CR22","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood.2020005673","volume":"137","author":"R Klamroth","year":"2021","unstructured":"Klamroth R, Windyga J, Radulescu V, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021;137:1818\u201327.","journal-title":"Blood"},{"key":"3032_CR23","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/hae.12987","volume":"22","author":"KW Wyrwich","year":"2016","unstructured":"Wyrwich KW, Krishnan S, Auguste P, et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016;22:866\u201372.","journal-title":"Haemophilia"},{"key":"3032_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","volume":"123","author":"J Mahlangu","year":"2014","unstructured":"Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317\u201325.","journal-title":"Blood"},{"key":"3032_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/hae.13144","volume":"23","author":"AD Shapiro","year":"2017","unstructured":"Shapiro AD, Mahlangu JN, Perry D, et al. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017;23:392\u20139.","journal-title":"Haemophilia"},{"key":"3032_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1160\/TH16-06-0444","volume":"117","author":"P Giangrande","year":"2017","unstructured":"Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117:252\u201361.","journal-title":"Thromb Haemost"},{"key":"3032_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2147\/PPA.S196103","volume":"13","author":"S Kearney","year":"2019","unstructured":"Kearney S, Raffini LJ, Pham TP, et al. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII. Patient Prefer Adherence. 2019;13:497\u2013513.","journal-title":"Patient Prefer Adherence"},{"key":"3032_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.13597","volume":"15","author":"MT Reding","year":"2017","unstructured":"Reding MT, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94\u20139027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017;15:411\u20139.","journal-title":"J Thromb Haemost"},{"key":"3032_CR29","doi-asserted-by":"crossref","unstructured":"Weyand A, Meunier S, Amano K, et al. Treatment of bleeding episodes with efanesoctocog alfa in patients with severe haemophilia A in the phase 3 XTEND-1 study. Haemophilia. 2023;29:136 (PO202).","DOI":"10.1055\/s-0044-1779119"},{"key":"3032_CR30","unstructured":"Phillippo DM, Ades A, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Report by the Decision Support Unit.; 2016."},{"key":"3032_CR31","unstructured":"R Core Team. A language and environment for statistical computing. Vienna, Austria; 2023."},{"key":"3032_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100176","volume":"7","author":"T Lissitchkov","year":"2023","unstructured":"Lissitchkov T, Willemze A, Jan C, Zilberstein M, Katragadda S. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa. Res Pract Thromb Haemost. 2023;7:100176.","journal-title":"Res Pract Thromb Haemost"},{"key":"3032_CR33","unstructured":"Spasov E, Quon D, Fukutake K, et al. Treatment preferences in previously treated patients with haemophilia A: Phase 3 XTEND-1 study of efanesoctocog alfa. Haemophilia. 2024;30 (S1):96 (PO123)."},{"key":"3032_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38:200\u201311.","journal-title":"Med Decis Making"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03032-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03032-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03032-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:03:19Z","timestamp":1738234999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03032-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03032-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"Alix Arnaud, Amanda Wilson, and Patricia Guyot are Sanofi employees and may hold stock\/stock options in Sanofi. Nana Kragh and Linda Bystrick\u00e1 are employees of Sobi and may hold stock\/stock options in Sobi. Piotr Wojciechowski is co-founder at Assignity and an external consultant at Putnam PHMR. Marlena Wdowiak and Wojciech Margas are employees of Putnam PHMR. Robert Klamroth has received honoraria and\/or been a member of advisory committees for Bayer, Biomarin, Biotest, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche\/Chugai, Sanofi, Sobi, and Takeda. Alberto Tosetto has no relevant conflicts of interest.\u00a0Piotr Wojciechowski\u2019s and Wojciech Margas\u2019 affiliation Assignity is now called Clever-Access.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is a post hoc analysis and modelling of data already collected and\/or published data. Original studies were all approved by the relevant institutional review boards at each study site and were carried out in accordance with the International Conference on Harmonisation good clinical practice guidelines and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}